注射用尼可地尔临床应用进展
|
摘要
近年来,随着冠心病的发病率逐年升高,接受经皮冠状动脉介入治疗的患者数量明显增加,随之而来的慢血流、无复流和再灌注心肌损伤等手术并发症也逐渐增多,严重影响了患者的预后。注射用尼可地尔作为一种具有开放ATP敏感性钾离子通道和类硝酸酯双重作用的药物,能够降低介入治疗并发症的风险,最近研究表明,其还可以显著改善急性心衰患者的症状及血流动力学。
The incidence of coronary heart disease is increasing year by year. With the development of percutaneous coronary intervention,surgical complications including slowflow,no reflowand myocardial reperfusion injury also gradually increase,seriously affecting the prognosis of patients and their quality of life. Nicorandil for injection,as a drug with dual function of nitrates and ATP-sensitive potassium channel agonist,can effectively reduce the risk of complications of intervention therapy. In recent years,the experiments have shown that nicorandil can also relieve acute heart failure and improve hemodynamics.
The incidence of coronary heart disease is increasing year by year. With the development of percutaneous coronary intervention,surgical complications including slowflow,no reflowand myocardial reperfusion injury also gradually increase,seriously affecting the prognosis of patients and their quality of life. Nicorandil for injection,as a drug with dual function of nitrates and ATP-sensitive potassium channel agonist,can effectively reduce the risk of complications of intervention therapy. In recent years,the experiments have shown that nicorandil can also relieve acute heart failure and improve hemodynamics.
引文
[1]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要[J].中国循环杂志,2018,33(1):1-8.
[2] Zhou SS,Tian F,Chen YD,et al. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction[J]. J Geriatr Cardiol,2015,12(2):135-142.
[3] Chen C,Fu X,Li W,et al. Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction:a randomized factorial trial[J]. Exp Ther M ed,2015,10(3):1059-1065.
[4]黄静静,罗助荣.注射用尼可地尔在急性冠状动脉综合征中的应用进展[J].心血管病学进展,2016,37(5):564-567.
[5]李江.尼可地尔治疗冠心病心绞痛的疗效观察[J].中国医学创新,2012,9(22):43-44.
[6] Iwaki F,Amano H,Ohura K. Nicorandil inhibits osteoclast differentiation in vitro[J]. Eur J Pharmacol,2016,793:14-20.
[7] Kostic J,Djordjevic-Dikic A,Dobric M,et al. The effects of nicorandil on microvascular function in patients w ith ST segment elevation myocardial infarction undergoing primary PCI[J]. Cardiovasc Ultrasound,2015,13:26.
[8] Yang J,Zhang J,Cui W,et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention[J]. Anatol J Cardiol,2015,15(2):125-131.
[9] Feng L,Qiu J,Ma J,et al. Cardioprotective effects of K(ATP)channel opener nicorandil during ischemia/reperfusion in dogs[J]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue,2005,17(3):157-160.
[10]南颖东.心肌缺血预适应的研究综述[J].陇东学院学报,2017,28(3):60-64.
[11]张迎,张敏,宁小康,等.尼可地尔对PCI术后再发不稳定型心绞痛患者的临床观察[J].陕西医学杂志,2015,44(6):749-751.
[12] Li W,Wu N,Shu W,et al. Pharmacological preconditioning and postconditioning w ith nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats[J]. Exp Ther M ed,2015,10(6):2197-2205.
[13] Zimarino M,Affinito V. The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions[J]. Cardiovasc Revasc Med,2013,14(1):32-36.
[14] Iwakura K,Ito H,Okamura A,et al. Nicorandil treatment in patients w ith acute myocardial infarction:a meta-analysis[J].Circ J,2009,73(5):925-931.
[15] Kawai Y,Hisamatsu K,Matsubara H,et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon[J]. Eur Heart J,2009,30(7):765-772.
[16] Kawakita N,Ejiri K,Miyoshi T,et al. Protective effect of nicorandil on myocardial injury follow ing percutaneous coronary intervention in older patients w ith stable coronary artery disease:secondary analysis of a randomized,controlled trial(RINC)[J]. PLoS One,2018,13(4):e0194623.
[17] Wang S,Fan Y,Feng X,et al. Nicorandil alleviates myocardial injury and post-infarction cardiac remodeling by inhibiting Mst1[J]. Biochem Biophys Res Commun,2018,495(1):292-299.
[18]王志清,陈梅贤,刘东林,等.预防性冠状动脉内注射尼可地尔对急性ST段抬高型心肌梗死介入治疗后心肌血流灌注及预后的影响[J].中华心血管病杂志,2017,45(1):26-33.
[19] Harada K,Yamamoto T,Okumura T,et al. Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes:a randomized,controlled trial[J]. Eur Heart J Acute Cardiovasc Care,2017,6(4):329-338.
[20] Ishihara S,Koga T,Kaseda S,et al. Effects of intravenous nicorandil on the mid-term prognosis of patients w ith acute heart failure syndrome[J]. Circ J,2012,76(5):1169-1176.
[21] Tanaka K,Kato K,Takano T,et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized w ith acute decompensated heart failure[J]. J Cardiol,2010,56(3):291-299.
[22] Hattori H,Minami Y,Mizuno M,et al. Differences in hemodynamic responses betw een intravenous carperitide and nicorandil in patients w ith acute heart failure syndromes[J]. Heart Vessels,2013,28(3):345-351.
[23] Minami Y,Nagashima M,Kajimoto K,et al. Acute efficacy and safety of intravenous administration of nicorandil in patients w ith acute heart failure syndromes:usefulness of noninvasive echocardiographic hemodynamic evaluation[J]. J Cardiovasc Pharmacol,2009,54(4):335-340.
[24] Shirakabe A,Hata N,Yokoyama S,et al. Efficacy and safety of nicorandil therapy in patients w ith acute heart failure[J]. J Cardiol,2010,56(3):339-347.
[25] Kasama S,Toyama T,Funada R,et al. Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients w ith acute decompensated heart failure[J]. Eur J Nucl M ed M ol Imaging,2015,42(5):761-770.
[26] Nawa T,Nishigaki K,Kinomura Y,et al. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients w ith poor renal function[J]. Int J Cardiol,2015,195:228-234.
[27] Ko YG,Lee BK,Kang WC,et al. Preventive effect of pretreatment w ith intravenous nicorandil on contrast-induced nephropathy in patients w ith renal dysfunction undergoing coronary angiography(PRINCIPLE Study)[J]. Yonsei M ed J,2013,54(4):957-964.
[28] Wang X,Geng J,Zhu H,et al. Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials[J]. Oncotarget,2018,9(14):11837-11845.
[2] Zhou SS,Tian F,Chen YD,et al. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction[J]. J Geriatr Cardiol,2015,12(2):135-142.
[3] Chen C,Fu X,Li W,et al. Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction:a randomized factorial trial[J]. Exp Ther M ed,2015,10(3):1059-1065.
[4]黄静静,罗助荣.注射用尼可地尔在急性冠状动脉综合征中的应用进展[J].心血管病学进展,2016,37(5):564-567.
[5]李江.尼可地尔治疗冠心病心绞痛的疗效观察[J].中国医学创新,2012,9(22):43-44.
[6] Iwaki F,Amano H,Ohura K. Nicorandil inhibits osteoclast differentiation in vitro[J]. Eur J Pharmacol,2016,793:14-20.
[7] Kostic J,Djordjevic-Dikic A,Dobric M,et al. The effects of nicorandil on microvascular function in patients w ith ST segment elevation myocardial infarction undergoing primary PCI[J]. Cardiovasc Ultrasound,2015,13:26.
[8] Yang J,Zhang J,Cui W,et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention[J]. Anatol J Cardiol,2015,15(2):125-131.
[9] Feng L,Qiu J,Ma J,et al. Cardioprotective effects of K(ATP)channel opener nicorandil during ischemia/reperfusion in dogs[J]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue,2005,17(3):157-160.
[10]南颖东.心肌缺血预适应的研究综述[J].陇东学院学报,2017,28(3):60-64.
[11]张迎,张敏,宁小康,等.尼可地尔对PCI术后再发不稳定型心绞痛患者的临床观察[J].陕西医学杂志,2015,44(6):749-751.
[12] Li W,Wu N,Shu W,et al. Pharmacological preconditioning and postconditioning w ith nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats[J]. Exp Ther M ed,2015,10(6):2197-2205.
[13] Zimarino M,Affinito V. The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions[J]. Cardiovasc Revasc Med,2013,14(1):32-36.
[14] Iwakura K,Ito H,Okamura A,et al. Nicorandil treatment in patients w ith acute myocardial infarction:a meta-analysis[J].Circ J,2009,73(5):925-931.
[15] Kawai Y,Hisamatsu K,Matsubara H,et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon[J]. Eur Heart J,2009,30(7):765-772.
[16] Kawakita N,Ejiri K,Miyoshi T,et al. Protective effect of nicorandil on myocardial injury follow ing percutaneous coronary intervention in older patients w ith stable coronary artery disease:secondary analysis of a randomized,controlled trial(RINC)[J]. PLoS One,2018,13(4):e0194623.
[17] Wang S,Fan Y,Feng X,et al. Nicorandil alleviates myocardial injury and post-infarction cardiac remodeling by inhibiting Mst1[J]. Biochem Biophys Res Commun,2018,495(1):292-299.
[18]王志清,陈梅贤,刘东林,等.预防性冠状动脉内注射尼可地尔对急性ST段抬高型心肌梗死介入治疗后心肌血流灌注及预后的影响[J].中华心血管病杂志,2017,45(1):26-33.
[19] Harada K,Yamamoto T,Okumura T,et al. Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes:a randomized,controlled trial[J]. Eur Heart J Acute Cardiovasc Care,2017,6(4):329-338.
[20] Ishihara S,Koga T,Kaseda S,et al. Effects of intravenous nicorandil on the mid-term prognosis of patients w ith acute heart failure syndrome[J]. Circ J,2012,76(5):1169-1176.
[21] Tanaka K,Kato K,Takano T,et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized w ith acute decompensated heart failure[J]. J Cardiol,2010,56(3):291-299.
[22] Hattori H,Minami Y,Mizuno M,et al. Differences in hemodynamic responses betw een intravenous carperitide and nicorandil in patients w ith acute heart failure syndromes[J]. Heart Vessels,2013,28(3):345-351.
[23] Minami Y,Nagashima M,Kajimoto K,et al. Acute efficacy and safety of intravenous administration of nicorandil in patients w ith acute heart failure syndromes:usefulness of noninvasive echocardiographic hemodynamic evaluation[J]. J Cardiovasc Pharmacol,2009,54(4):335-340.
[24] Shirakabe A,Hata N,Yokoyama S,et al. Efficacy and safety of nicorandil therapy in patients w ith acute heart failure[J]. J Cardiol,2010,56(3):339-347.
[25] Kasama S,Toyama T,Funada R,et al. Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients w ith acute decompensated heart failure[J]. Eur J Nucl M ed M ol Imaging,2015,42(5):761-770.
[26] Nawa T,Nishigaki K,Kinomura Y,et al. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients w ith poor renal function[J]. Int J Cardiol,2015,195:228-234.
[27] Ko YG,Lee BK,Kang WC,et al. Preventive effect of pretreatment w ith intravenous nicorandil on contrast-induced nephropathy in patients w ith renal dysfunction undergoing coronary angiography(PRINCIPLE Study)[J]. Yonsei M ed J,2013,54(4):957-964.
[28] Wang X,Geng J,Zhu H,et al. Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials[J]. Oncotarget,2018,9(14):11837-11845.